PET / CT With 18F-FDG: Does it Optimize the I 123-MIBG Imaging Results in the Search for Discriminating Factors for the Implementation of an Implantable Defibrillator?

PET / CT With 18F-FDG (18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography): Does it Optimize the I 123-MIBG (Iodine 123 Metaiodobenzylguanidine) Imaging Results in the Search for Discriminating Factors for the Implementation of an Implantable Defibrillator for Primary Prevention in Patients With Heart Failure of Ischemic Origin?

The main objective of this study is to determine among the patients included a subpopulation that does not need a defibrillator.

This will be done by comparing the number of discordant segments (mismatch) between patients who have a severe arrhythmia (ventricular tachycardia or ventricular fibrillation) with appropriate electrical therapy within 3 years of monitoring and others. "Mismatch" in the definition of this objective is the usual definition: score 3.4 in I123-MIBG (Iodine 123 metaiodobenzylguanidine) and PET at 0,1,2.

Inclusion Criteria:

• Patient with ischemic heart disease with heart failure
• Patients who received myocardial perfusion scintigraphy
• Indication for the implantation of an ICD installed according to current recommendations : LVEF <30% and NYHA (New York Heart Association) stage II, III.
• The subject must have given his informed consent and signed consent
• The subject must be a member or beneficiary of a social security system

Exclusion Criteria:

• Pregnant or lactating women
• History of "open heart" cardiovascular surgery
• Inability to sign informed consent (patient under guardianship)
• Patients with diabetes mellitus
• Patient with proven dementia
• Person refusing to sign the consent
• Someone who already has an ICD at baseline
• Life expectancy less than one year (NYHA IV, other diseases such as neoplastic disease in an advanced stage)